These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 14533142)

  • 41. [Depression and pain: novel clinical, neurobiological and psychopharmacological data].
    Jaracz J; Rybakowski J
    Psychiatr Pol; 2005; 39(5):937-50. PubMed ID: 16358593
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Milnacipran plasma levels and antidepressant response in Japanese major depressive patients.
    Higuchi H; Yoshida K; Takahashi H; Naito S; Kamata M; Ito K; Sato K; Tsukamoto K; Shimizu T; Nakanishi M; Hishikawa Y
    Hum Psychopharmacol; 2003 Jun; 18(4):255-9. PubMed ID: 12766929
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacology and pharmacokinetics of milnacipran.
    Puozzo C; Panconi E; Deprez D
    Int Clin Psychopharmacol; 2002 Jun; 17 Suppl 1():S25-35. PubMed ID: 12369608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [The clinical efficacy of SNRI milnacipran in the treatment of hot flushes with prostate cancer hormonally treated].
    Suzuki H; Komiya A; Kojima S; Tobe T; Ueda T; Ichikawa T
    Hinyokika Kiyo; 2007 Jun; 53(6):375-9. PubMed ID: 17628934
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Pharmacokinetics and drug interactions of antidepressive agents].
    Sawada Y; Ohtani H
    Nihon Rinsho; 2001 Aug; 59(8):1539-45. PubMed ID: 11519155
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Adverse effects of antidepressants and antimanics].
    Tanaka T; Koyama T
    Ryoikibetsu Shokogun Shirizu; 2003; (38):362-5. PubMed ID: 12877003
    [No Abstract]   [Full Text] [Related]  

  • 47. Effect of chronic treatment with milnacipran on sleep architecture in rats compared with paroxetine and imipramine.
    Gervasoni D; Panconi E; Henninot V; Boissard R; Barbagli B; Fort P; Luppi PH
    Pharmacol Biochem Behav; 2002 Oct; 73(3):557-63. PubMed ID: 12151030
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Medication to treat fibromyalgia?].
    Perrot S
    Rev Med Suisse; 2007 Jun; 3(116):1575-8. PubMed ID: 17727168
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Addition of a dopamine agonist, cabergoline, to a serotonin-noradrenalin reuptake inhibitor, milnacipran as a therapeutic option in the treatment of refractory depression: two case reports.
    Takahashi H; Yoshida K; Higuchi H; Shimizu T; Inoue T; Koyama T
    Clin Neuropharmacol; 2003; 26(5):230-2. PubMed ID: 14520161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The interaction between antidepressant drugs and the pain-relieving effect of spinal cord stimulation in a rat model of neuropathy.
    Song Z; Meyerson BA; Linderoth B
    Anesth Analg; 2011 Nov; 113(5):1260-5. PubMed ID: 21788322
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of painful physical symptoms in the treatment of Japanese patients with melancholic major depressive disorder: A prospective cohort study.
    Sekine A; Hozumi S; Shimizu T
    Psychiatry Res; 2016 Aug; 242():240-244. PubMed ID: 27294798
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The evaluation of analgesic effects of milnacipran and sertraline in tail-flick test.
    Kesim M; Yanik MN; Kadioglu M; Pepeoglu D; Erkoseoglu I; Kalyoncu NI; Yaris E
    Bratisl Lek Listy; 2014; 115(1):3-6. PubMed ID: 24471894
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran.
    Yoshida K; Higuchi H; Takahashi H; Kamata M; Sato K; Inoue K; Suzuki T; Itoh K; Ozaki N
    Hum Psychopharmacol; 2008 Mar; 23(2):121-8. PubMed ID: 18023073
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Management of phantom limb pain and sensation with milnacipran.
    Sato K; Higuchi H; Hishikawa Y
    J Neuropsychiatry Clin Neurosci; 2008; 20(3):368. PubMed ID: 18806244
    [No Abstract]   [Full Text] [Related]  

  • 55. Pharmacological treatment of fibromyalgia and other chronic musculoskeletal pain.
    Goldenberg DL
    Best Pract Res Clin Rheumatol; 2007 Jun; 21(3):499-511. PubMed ID: 17602996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder.
    Papakostas GI; Fava M
    Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Preclinical pharmacology of milnacipran.
    Briley M; Prost JF; Moret C
    Int Clin Psychopharmacol; 1996 Sep; 11 Suppl 4():9-14. PubMed ID: 8923122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Successful treatment of severe antidepressant-induced nausea with a combination of milnacipran and olanzapine.
    Yoshida K; Higuchi H; Ozaki N
    Pharmacopsychiatry; 2007 Mar; 40(2):84-5. PubMed ID: 17447181
    [No Abstract]   [Full Text] [Related]  

  • 59. Raynaud's syndrome in a patient treated with milnacipran.
    Bourgade B; Jonville-Béra AP; Le Garé C; Ferquel D; Autret-Leca E
    Ann Pharmacother; 1999 Sep; 33(9):1009-10. PubMed ID: 10492510
    [No Abstract]   [Full Text] [Related]  

  • 60. Milnacipran: a dual norepinephrine and serotonin reuptake pump inhibitor.
    Preskorn SH
    J Psychiatr Pract; 2004 Mar; 10(2):119-26. PubMed ID: 15330407
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.